Abstract: Objective To explore the effect of sacubitril/valsartan on myocardial injury and inflammatory indexes in patients with ischemic cardiomyopathy with reduced ejection fraction, so as to provide evidence for the treatment of heart failure caused by ischemia. Methods Eighty-four patients with ischemic cardiomyopathy complicated with heart failure who were hospitalized in the Affiliated Hospital of Hangzhou Normal University from January 2019 to December 2019 were selected as the research object. They were divided into observation group(42 cases) and control group(42 cases) by random number table method. The observation group was treated with sacubitril/valsartan, and the control group was treated with valsartan. Myocardial injury and inflammation indexes were compared between the two groups after 4 weeks of treatment. Results After 4 weeks of treatment, the average level of N-terminal prohormone of brain natriuretic peptide(NT-proBNP) in the observation group was(1 726.36±492.37) pg/mL, the average level of cardiac troponin I(cTnI) was(19.27±4.38) ng/L, and the above indexes in the control group were(2 833.37±503.44) pg/mL,(22.39±5.02) ng/L, respectively, the difference was statistically significant(t=10.188 and 3.035, all P<0.05). In the observation group, the high-sensitivity C-reactive protein(hs-CRP) level was(5.48±1.28) mg/L, IL-6 level was(18.36±3.38) pg/mL, TNF-α level was(5.32±1.27) pg/mL, and IFN-γ level was(6.67±1.17) pg/mL, the above indexes of the control group were(6.85±1.37) mg/L,(21.29±3.22) pg/mL,(8.34±1.87) pg/mL,(9.30±1.20) pg/mL, respectively. The level of inflammatory factors in the observation group were lower than those in the control group(all P<0.05). Conclusion sacubitril/valsartan can repair myocardial injury in patients with ischemic cardiomyopathy and reduce inflammation in heart failure in a short time.